SOURCE: Transdel Pharmaceuticals

October 31, 2007 09:00 ET

Transdel Pharmaceuticals to Present at the Rodman & Renshaw 9th Annual Healthcare Conference

LA JOLLA, CA--(Marketwire - October 31, 2007) - Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically targeted medications, today announced that Dr. Juliet Singh, President and Chief Executive Officer, will present at the Rodman and Renshaw 9th Annual Healthcare Conference on Wednesday, November 7th at 3:00 p.m. Eastern Time at the New York Palace Hotel in Hubbard located on the 5th floor.

For those investors unable to attend the conference in person, a live Webcast of the presentation can be heard at http://www.wsw.com/webcast/rrshq12/tdlp.ob and will be archived for replay.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel™, utilizes the Company's innovative proprietary Transdel™ cream formulation to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel™ platform technology for products in pain management and other therapeutic areas.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    For further information, please contact:
    Alliance Advisors
    Thomas P. Walsh
    212-398-3486
    Email Contact

    or

    John Lomoro
    CFO
    Transdel Pharmaceuticals, Inc.
    858-457-5300
    Email Contact